AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales ...

(RTTNews) - AVITA Medical, Inc. (RCEL), a regenerative medicine company focused on innovative wound care solutions, announced that the U.S. Food and Drug Administration has approved its premarket ...